LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio sat down with new member SenseUp, to find out about the natural evolution approach for novel protein and RNA products

13/12/2022
INTERVIEW

About Georg Schaumann
Georg studied biology in Düsseldorf and Aachen, before inventing single-cell biosensors for microbial strain development by natural evolution for his PhD at Forschungszentrum Jülich. He started SenseUP as a spin-off project in 2015, and raised funding with Helmholtz-Enterprise, GO-Bio phase I & II accompanied by two seed-financing rounds. SenseUP GmbH began commercial activity in mid 2017 and today has an active team of 12 and has received awards from German, European and global institutions. Georg is a father of two and lives in Cologne.

Interview with Dr. Georg Schaumann, CEO and Founder at SenseUP

1) What inspired the foundation of SenseUp?

SenseUP was founded by scientists with the desire to translate great scientific achievements into real-world applications. We believe that science and technology will strongly contribute to solving the world’s biggest problems. But to do so, they must be  implemented in industrial applications and that’s what SenseUP was founded for and is delivering on now.

2) What are the policy areas which offer opportunities and potential challenges for SenseUp?

Opportunities: Bio-technologies such as ours will enable the transition of many industrial sectors away from an oil, chemical or animal base to new solutions that better support environmental goals and a growing population. Policies that support environmental and climate regulation can accelerate this transition.

Challenges: In Europe, the regulatory process for novelty products is extremely long and complex. We need this to change to avoid innovation migrating to more accommodating parts of the world.

3) What are your plans for growth?

Since 2019, SenseUP has been working on an RNA program to explore and identify novel applications with strong commercial value. We have now started developing a range of RNA products based on microbial fermentation using SenseUp’s patented Corynebacterium and natural evolution technology.

Our aim is to develop sustainable and effective commercial products that are ready for industrial-scale production at low cost and can be launched in the years to come in cooperation with strategic industrial partners.

4) How do you see SenseUp being able to transform the biotech industry?

By delivering on our vision! This is: “Enabling a healthy and sustainable future by unlocking the path to valuable proteins and RNA”

RNA has revolutionary potential as a therapeutic agent for both human and animal health, as well as for use as a biopesticide in agriculture.

We are targeting animal parasites and plant pathogens that cause financial losses worth billions of Euros, in addition to positive impact on human, animal and environmental health.

Interview with SenseUp


Download
2022_12_G_O_Interview-with-New-Member-SenseUpDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

10/06/2025

EuropaBio Position on the EU Biotech Act: Prosperity, resilience and leadership for the European Union


Read more
10/06/2025

The EU economic and scientific future starts with the EU Biotech Act


Read more
05/06/2025

The GPL must include biotech & life science to unleash EU innovation


Read more

Important links

  • EuropaBio Position on the EU Biotech Act: Prosperity, resilience and leadership for the European Union
  • The EU economic and scientific future starts with the EU Biotech Act

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.